172 related articles for article (PubMed ID: 33830642)
1. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.
Pollak M; Shaw M; Wilson D; Solomon M; Ratjen F; Grasemann H
Pediatr Pulmonol; 2021 Jul; 56(7):2036-2042. PubMed ID: 33830642
[TBL] [Abstract][Full Text] [Related]
2. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
4. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
5. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
6. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
7. Home-spirometry exacerbation profiles in children with cystic fibrosis.
Bouteleux B; Beaufils F; Fayon M; Bui S
Pediatr Pulmonol; 2024 Mar; 59(3):552-561. PubMed ID: 38014613
[TBL] [Abstract][Full Text] [Related]
8. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
[TBL] [Abstract][Full Text] [Related]
9. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
10. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
Heltshe SL; Russell R; VanDevanter DR; Sanders DB
J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
[TBL] [Abstract][Full Text] [Related]
11. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations.
Zikic A; Ratjen F; Shaw M; Tullis E; Waters V
J Cyst Fibros; 2022 Sep; 21(5):759-765. PubMed ID: 35650003
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
13. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
15. Treatment response to pulmonary exacerbation in primary ciliary dyskinesia.
Gatt D; Shaw M; Waters V; Kritzinger F; Solomon M; Dell S; Ratjen F
Pediatr Pulmonol; 2023 Oct; 58(10):2857-2864. PubMed ID: 37449771
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis.
Marson FA; Bertuzzo CS; Ribeiro AF; Ribeiro JD
BMC Pulm Med; 2012 Sep; 12():50. PubMed ID: 22950544
[TBL] [Abstract][Full Text] [Related]
17. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
18. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]